The Question Every Man on TRT Wants Answered
Among the concerns that most frequently cause men to hesitate before pursuing testosterone replacement therapy, prostate health ranks near the top. The intuitive worry — “won’t more testosterone make my prostate grow, or worse, fuel prostate cancer?” — seems biologically logical. Prostate cancer is hormonally sensitive; castration (which eliminates testosterone) is an established treatment for advanced prostate cancer. So surely adding testosterone must be risky?
The reality is far more nuanced, and the evidence has shifted considerably over the past two decades in ways that are reassuring for most men considering TRT. Understanding what the science actually shows — rather than what intuition might suggest — is essential for informed decision-making.
The Saturation Model
The prevailing historical model — that higher testosterone drives prostate cancer growth — led to decades of testosterone avoidance in men with prostate concerns. But this model has been fundamentally challenged by the “saturation model,” proposed by Dr. Abraham Morgentaler, which suggests that prostate cells have a finite capacity to respond to androgens. Once androgen receptors are saturated — which occurs at relatively low testosterone levels — adding more testosterone produces no additional prostate stimulation. This explains why castrate-level testosterone dramatically shrinks prostate cancer, but restoring testosterone from low-normal to optimal levels does not.
Supporting the saturation model: studies have found no correlation between normal-range testosterone levels and prostate cancer risk. In fact, some studies have found that men with low testosterone have higher rates of aggressive prostate cancer — the opposite of what the old “testosterone feeds cancer” model would predict. A large meta-analysis found no increased risk of prostate cancer in men receiving TRT. And epidemiological data consistently shows that prostate cancer incidence rises in older men when testosterone levels are typically at their lowest.
TRT and Benign Prostatic Hyperplasia (BPH)
Benign prostatic hyperplasia — prostate enlargement that causes urinary symptoms — is a separate concern from prostate cancer and requires its own discussion. Testosterone can stimulate prostate tissue growth, and DHT (dihydrotestosterone) — the more potent androgen produced from testosterone by the enzyme 5-alpha reductase — is the primary driver of prostate growth. Men on TRT can experience modest increases in prostate volume and PSA (prostate-specific antigen). Importantly, these changes are typically modest and do not appear to accelerate BPH progression beyond what would occur with aging. Monitoring PSA and urinary symptoms is standard practice in TRT management, allowing for early detection of any clinically significant prostate changes.
Who Should Not Use TRT Without Careful Evaluation
While the evidence is reassuring for most men, certain groups require particularly careful evaluation: men with untreated prostate cancer (TRT is generally contraindicated in men with active prostate cancer), men with rapidly rising PSA on monitoring, men with severe lower urinary tract symptoms from BPH, and men with a strong family history of prostate cancer. In these individuals, the risk-benefit assessment must be individualized, and any TRT should involve close collaboration with a urologist alongside the prescribing hormone practitioner.
For most hypogonadal men with normal baseline PSA and no active prostate pathology, the evidence supports TRT as safe from a prostate standpoint when properly monitored. The fear-driven avoidance of testosterone therapy that has left millions of men suffering from untreated hypogonadism is not supported by the current scientific evidence — but neither should prostate health be ignored. Informed, monitored TRT is the standard of care.